These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35964686)

  • 1. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
    Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
    Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
    Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
    Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
    Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
    Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
    Myöhänen TT; Norrbacka S; Savolainen MH
    Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
    Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
    Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
    Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
    Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effect of β-Wrapin AS69 in a Mouse Model Based on Alpha-Synuclein Overexpression.
    Höfs L; Geißler-Lösch D; Wunderlich KM; Szegö EM; Van den Haute C; Baekelandt V; Hoyer W; Falkenburger BH
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
    Dokleja L; Hannula MJ; Myöhänen TT
    Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
    Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
    Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
    Cui H; Norrbacka S; Myöhänen TT
    Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
    Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
    Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.
    Kilpeläinen TP; Pätsi HT; Svarcbahs R; Julku UH; Eteläinen TS; Cui H; Auno S; Sipari N; Norrbacka S; Leino TO; Jäntti M; Myöhänen TT; Wallén EAA
    J Med Chem; 2023 Jun; 66(11):7475-7496. PubMed ID: 37248563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.
    Schlichtmann BW; Palanisamy BN; Malovic E; Nethi SK; Padhi P; Hepker M; Wurtz J; John M; Ban B; Anantharam V; Kanthasamy AG; Narasimhan B; Mallapragada SK
    Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.
    Suzuki M; Fujikake N; Takeuchi T; Kohyama-Koganeya A; Nakajima K; Hirabayashi Y; Wada K; Nagai Y
    Hum Mol Genet; 2015 Dec; 24(23):6675-86. PubMed ID: 26362253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
    Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
    Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.